Cargando…

Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review

One-fourth to one-third of women with endometriosis receiving first-line hormonal treatment lacks an adequate response in terms of resolution of painful symptoms. This phenomenon has been ascribed to “progesterone resistance”, an entity that was theorized to explain the gap between the ubiquity of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cetera, Giulia Emily, Merli, Camilla Erminia Maria, Facchin, Federica, Viganò, Paola, Pesce, Elisa, Caprara, Francesca, Vercellini, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311799/
https://www.ncbi.nlm.nih.gov/pubmed/37391793
http://dx.doi.org/10.1186/s12905-023-02490-1
_version_ 1785066817502314496
author Cetera, Giulia Emily
Merli, Camilla Erminia Maria
Facchin, Federica
Viganò, Paola
Pesce, Elisa
Caprara, Francesca
Vercellini, Paolo
author_facet Cetera, Giulia Emily
Merli, Camilla Erminia Maria
Facchin, Federica
Viganò, Paola
Pesce, Elisa
Caprara, Francesca
Vercellini, Paolo
author_sort Cetera, Giulia Emily
collection PubMed
description One-fourth to one-third of women with endometriosis receiving first-line hormonal treatment lacks an adequate response in terms of resolution of painful symptoms. This phenomenon has been ascribed to “progesterone resistance”, an entity that was theorized to explain the gap between the ubiquity of retrograde menstruation and the 10% prevalence of endometriosis among women of reproductive age. Nevertheless, the hypothesis of progesterone resistance is not free of controversies. As our understanding of endometriosis is increasing, authors are starting to set aside the traditionally accepted tunnel vision of endometriosis as a strictly pelvic disease, opening to a more comprehensive perspective of the condition. The question is: are patients not responding to first-line treatment because they have an altered signaling pathway for such treatment, or have we been overlooking a series of other pain contributors which may not be resolved by hormonal therapy? Finding an answer to this question is evermore impelling, for two reasons mainly. Firstly, because not recognizing the presence of further pain contributors adds a delay in treatment to the already existing delay in diagnosis of endometriosis. This may lead to chronicity of the untreated pain contributors as well as causing adverse consequences on quality of life and psychological health. Secondly, misinterpreting the consequences of untreated pain contributors as a non-response to standard first-line treatment may imply the adoption of second-line medical therapies or of surgery, which may entail non-negligible side effects and may not be free of physical, psychological and socioeconomic repercussions. The current narrative review aims at providing an overview of all the possible pain contributors in endometriosis, ranging from those strictly organic to those with a greater neuro-psychological component. Including these aspects in a broader psychobiological approach may provide useful suggestions for treating those patients who report persistent pain symptoms despite receiving first-line hormonal medical treatment.
format Online
Article
Text
id pubmed-10311799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103117992023-07-01 Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review Cetera, Giulia Emily Merli, Camilla Erminia Maria Facchin, Federica Viganò, Paola Pesce, Elisa Caprara, Francesca Vercellini, Paolo BMC Womens Health Review One-fourth to one-third of women with endometriosis receiving first-line hormonal treatment lacks an adequate response in terms of resolution of painful symptoms. This phenomenon has been ascribed to “progesterone resistance”, an entity that was theorized to explain the gap between the ubiquity of retrograde menstruation and the 10% prevalence of endometriosis among women of reproductive age. Nevertheless, the hypothesis of progesterone resistance is not free of controversies. As our understanding of endometriosis is increasing, authors are starting to set aside the traditionally accepted tunnel vision of endometriosis as a strictly pelvic disease, opening to a more comprehensive perspective of the condition. The question is: are patients not responding to first-line treatment because they have an altered signaling pathway for such treatment, or have we been overlooking a series of other pain contributors which may not be resolved by hormonal therapy? Finding an answer to this question is evermore impelling, for two reasons mainly. Firstly, because not recognizing the presence of further pain contributors adds a delay in treatment to the already existing delay in diagnosis of endometriosis. This may lead to chronicity of the untreated pain contributors as well as causing adverse consequences on quality of life and psychological health. Secondly, misinterpreting the consequences of untreated pain contributors as a non-response to standard first-line treatment may imply the adoption of second-line medical therapies or of surgery, which may entail non-negligible side effects and may not be free of physical, psychological and socioeconomic repercussions. The current narrative review aims at providing an overview of all the possible pain contributors in endometriosis, ranging from those strictly organic to those with a greater neuro-psychological component. Including these aspects in a broader psychobiological approach may provide useful suggestions for treating those patients who report persistent pain symptoms despite receiving first-line hormonal medical treatment. BioMed Central 2023-06-30 /pmc/articles/PMC10311799/ /pubmed/37391793 http://dx.doi.org/10.1186/s12905-023-02490-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Cetera, Giulia Emily
Merli, Camilla Erminia Maria
Facchin, Federica
Viganò, Paola
Pesce, Elisa
Caprara, Francesca
Vercellini, Paolo
Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
title Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
title_full Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
title_fullStr Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
title_full_unstemmed Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
title_short Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
title_sort non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311799/
https://www.ncbi.nlm.nih.gov/pubmed/37391793
http://dx.doi.org/10.1186/s12905-023-02490-1
work_keys_str_mv AT ceteragiuliaemily nonresponsetofirstlinehormonaltreatmentforsymptomaticendometriosisovercomingtunnelvisionanarrativereview
AT merlicamillaerminiamaria nonresponsetofirstlinehormonaltreatmentforsymptomaticendometriosisovercomingtunnelvisionanarrativereview
AT facchinfederica nonresponsetofirstlinehormonaltreatmentforsymptomaticendometriosisovercomingtunnelvisionanarrativereview
AT viganopaola nonresponsetofirstlinehormonaltreatmentforsymptomaticendometriosisovercomingtunnelvisionanarrativereview
AT pesceelisa nonresponsetofirstlinehormonaltreatmentforsymptomaticendometriosisovercomingtunnelvisionanarrativereview
AT caprarafrancesca nonresponsetofirstlinehormonaltreatmentforsymptomaticendometriosisovercomingtunnelvisionanarrativereview
AT vercellinipaolo nonresponsetofirstlinehormonaltreatmentforsymptomaticendometriosisovercomingtunnelvisionanarrativereview